Top 10 Oncology Stocks to Buy Now

7. Nuvation Bio Inc. (NYSE:NUVB)

Number of Hedge Fund Holders: 39

Nuvation Bio Inc. (NYSE:NUVB) stands seventh on our list among the best oncology stocks.

TheFly reported on January 12 that H.C. Wainwright reduced its price target on NUVB to $17 from $18 while maintaining a Buy rating. The firm said the company’s fourth-quarter Ibtrozi sales came in line with expectations.

On the same day, NUVB reported preliminary Q4 2025 net product revenue of approximately $15.7 million for IBTROZI (taletrectinib). The company also highlighted that 216 new patients started treatment with IBTROZI in the fourth quarter and received a $25 million milestone payment from Nippon Kayaku

Nuvation Bio Inc. (NYSE:NUVB) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for oncology patients. Its lead asset, IBTROZI (taletrectinib), targets rare and difficult-to-treat cancers. The company emphasizes precision medicine, pipeline expansion, and improving outcomes for patients with limited therapeutic options in oncology.